Efforts to vaccinate the world’s population against COVID-19 is garnering ample attention. Some vaccines provide strong, one-dose protection. The vaccines can later be frozen in normal freezers as opposed to ultra-cold ones.
According to the research by Israel and future research by Oxford University, vaccines by Pfizer Inc. and BioNTech SE generate immunity after one dose. Another AstraZeneca PLC vaccine prevented Covid-19 when doses were spaced three months apart.
These findings have resulted in the arguments of the second shot of covid 19 vaccines and in favor of delaying the second shot. They could have changed the vaccine policy and the distribution of the vaccine.
Pfizer and BioNTech vaccine companies said they had asked the US to store the vaccines and transport them at a consistent temperature, around minus 20 Celsius.
Industrial experts and officials said that if the Pfizer request is granted, then the vaccines will be available in rural areas and pharmacies and physician offices.
This label change would allow the poor countries who could not afford ultra cold Temperatures and make it much easier to use. Pfizer’s vaccine would also be able to return to ultracold temperatures after standard temperatures.
Ivan Dikic, director of the Institute of Biochemistry II at Goethe University Frankfurt, said this is a piece of excellent news and will greatly improve vaccine distribution. This protocol will make the vaccine accessible to both poor and rich countries.
The requirement for ultra-cold storage of the shots has been a major obstacle for some vaccine providers and health departments. Due to limited storage space, only limited doses were distributed. In the German state of Bavaria, 2,000 doses were discarded due to exposure to higher temperatures.
Pfizer vaccine researchers found that the two-dose regimen to be 95% effective at protecting against symptomatic Covid-19. The study found the vaccine to be more than 52% effective after one shot. This study was conducted on 44,000-person.